JinMatrix Obtains US Patent for Multiplex Molecular Diagnostic Core Technology
[Asia Economy Reporter Moon Hyewon] JinMatrix announced on the 8th that it has obtained a US patent for its proprietary multiplex molecular diagnostic core technology, ‘C-Tag’.
The patented technology is a platform used in the Neoplex multiplex molecular diagnostic product line. The company explained that it is recognized as a next-generation core technology capable of advanced multiplexing, surpassing the previously known limit of up to five simultaneous analyses in conventional real-time PCR technology.
Hot Picks Today
!["Delisted Because of Failure? Not a Chance"... Hyundai Department Store Group Upsets the Game With 500 Billion War Chest [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/93/2026012709331016647_1769473990.jpg)
"Delisted Because of Failure? Not a Chance"... Hyundai Department Store Group Upsets the Game With 500 Billion War Chest [Why&Next]
- "Don't Be Fooled by the Index Crash"..."Switch Here When Semiconductors Waver" [Weekend Money]
- "41.6 Degrees Reached, But Next Week Will Be Hotter"... Fear Grows Over Super Typhoon Dolphin With 56 m/s Winds
- Meta's Ambitious Glasses Boast "No More Secret Filming"... Rendered Useless by a Mere $2 Sticker
- "60,000 Cross in a Single Day" Unprecedented Human Wave... "A Disaster," Trump Laments
JinMatrix is currently preparing a comprehensive respiratory virus panel rapid diagnostic product applying the C-Tag core technology to its COVID-19 diagnostic products, which are being exported to Europe, the Middle East, and other regions.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
